These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 20061792)

  • 1. Molecular vaccines for malaria.
    Bruder JT; Angov E; Limbach KJ; Richie TL
    Hum Vaccin; 2010 Jan; 6(1):54-77. PubMed ID: 20061792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria.
    Halbroth BR; Sebastian S; Salman AM; Ulaszewska M; Gola A; Longley RJ; Janse CJ; Khan SM; Hill AVS; Spencer AJ
    Infect Immun; 2020 Jan; 88(2):. PubMed ID: 31740525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing immune responses against Plasmodium for rational vaccine design.
    Douradinha B; Doolan DL
    Trends Parasitol; 2011 Jun; 27(6):274-83. PubMed ID: 21531627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile.
    Collins WE; Pye D; Crewther PE; Vandenberg KL; Galland GG; Sulzer AJ; Kemp DJ; Edwards SJ; Coppel RL; Sullivan JS
    Am J Trop Med Hyg; 1994 Dec; 51(6):711-9. PubMed ID: 7810803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'.
    Takala SL; Plowe CV
    Parasite Immunol; 2009 Sep; 31(9):560-73. PubMed ID: 19691559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mixed allele malaria vaccines: host protection and within-host selection.
    Barclay VC; Chan BH; Anders RF; Read AF
    Vaccine; 2008 Nov; 26(48):6099-107. PubMed ID: 18804509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric parasites as tools to study Plasmodium immunology and assess malaria vaccines.
    Cockburn I
    Methods Mol Biol; 2013; 923():465-79. PubMed ID: 22990798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmodium p25 and p28 surface proteins: potential transmission-blocking vaccines.
    Saxena AK; Wu Y; Garboczi DN
    Eukaryot Cell; 2007 Aug; 6(8):1260-5. PubMed ID: 17557884
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic Cell Responses and Function in Malaria.
    Yap XZ; Lundie RJ; Beeson JG; O'Keeffe M
    Front Immunol; 2019; 10():357. PubMed ID: 30886619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-erythrocytic malaria vaccines: identifying the targets.
    Duffy PE; Sahu T; Akue A; Milman N; Anderson C
    Expert Rev Vaccines; 2012 Oct; 11(10):1261-80. PubMed ID: 23176657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination against malaria: targets, strategies and potentiation of immunity to blood stage parasites.
    Taylor-Robinson AW
    Front Biosci; 2000 Jan; 5():E16-29. PubMed ID: 10702381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
    Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naked DNA for malaria vaccines.
    Fricker J
    Mol Med Today; 1996 Mar; 2(3):91. PubMed ID: 8846464
    [No Abstract]   [Full Text] [Related]  

  • 16. Designing malaria vaccines to circumvent antigen variability.
    Ouattara A; Barry AE; Dutta S; Remarque EJ; Beeson JG; Plowe CV
    Vaccine; 2015 Dec; 33(52):7506-12. PubMed ID: 26475447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orally delivered malaria vaccines: not too hard to swallow.
    Wang L; Webster DE; Wesselingh SL; Coppel RL
    Expert Opin Biol Ther; 2004 Oct; 4(10):1585-94. PubMed ID: 15461570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malaria vaccine development using synthetic peptides as a technical platform.
    Corradin G; Céspedes N; Verdini A; Kajava AV; Arévalo-Herrera M; Herrera S
    Adv Immunol; 2012; 114():107-49. PubMed ID: 22449780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The path of malaria vaccine development: challenges and perspectives.
    Arama C; Troye-Blomberg M
    J Intern Med; 2014 May; 275(5):456-66. PubMed ID: 24635625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes.
    Westerfeld N; Pluschke G; Zurbriggen R
    Wien Klin Wochenschr; 2006; 118(19-20 Suppl 3):50-7. PubMed ID: 17131241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.